Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005239-22
    Sponsor's Protocol Code Number:BHV3000-404
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2022-09-06
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-005239-22
    A.3Full title of the trial
    A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens
    Studio di Fase 4, randomizzato, in doppio cieco, controllato con placebo volto a valutare l’efficacia e la sicurezza di rimegepant nella prevenzione dell’emicrania episodica con regimi di dosaggio multipli
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The purpose of this study is to compare the efficacy and safety of daily and
    every other day dosing of rimegepant to placebo as a preventive treatment
    for episodic migraine.
    Lo scopo di questo studio è quello di confrontare l'efficacia e la sicurezza
    ogni altro giorno dosaggio di rimegepant al placebo come trattamento preventivo
    per l'emicrania episodica
    A.3.2Name or abbreviated title of the trial where available
    BHV3000-404
    BHV3000-404
    A.4.1Sponsor's protocol code numberBHV3000-404
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05217927
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPFIZER INC
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiohaven Pharmaceuticals Holding Company Limited
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinical Trials.gov Call Center
    B.5.3 Address:
    B.5.3.1Street Address66 Hudson Boulevard East
    B.5.3.2Town/ cityNew York
    B.5.3.3Post code1001
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18007181021
    B.5.6E-mailClinicalTrials.gov_Inquiries@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vydura
    D.2.1.1.2Name of the Marketing Authorisation holderBiohaven Pharmaceutical Ireland DAC
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRimegepant 75mg
    D.3.2Product code [PF-07899801]
    D.3.4Pharmaceutical form Orodispersible tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRimegepant
    D.3.9.2Current sponsor codeBHV3000
    D.3.9.4EV Substance CodeSUB215832
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number75
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOrodispersible tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Acute Migraine (with or without aura)
    Emicrania acuta (con o senza aura)
    E.1.1.1Medical condition in easily understood language
    Migraine
    Emicrania
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of EOD and daily rimegepant dosing regimens relative to placebo as a preventive treatment for episodic migraine, as measured by the mean reduction from the Observation Phase in the number of migraine days per month over the entire Double-blind Treatment Phase.
    Valutare l’efficacia dei regimi di dosaggio EOD e giornalieri di rimegepant rispetto al placebo come trattamento preventivo per l’emicrania episodica, misurata in base alla riduzione media dalla Fase di osservazione nel numero di giorni di emicrania al mese nell’intera Fase di trattamento in doppio cieco.
    E.2.2Secondary objectives of the trial
    Evaluate the proportion of subjects with >50% reduction from the
    Observation Phase(OP) in the # of moderate to severe migraine days per
    month(dpm)over the entire Double-blind Treatment Phase(DBT) for the
    EOD and daily rimegepant dosing regimens relative to placebo(P)
    Evaluate the mean reduction from the OP in the # of migraine dpm in the
    last 4 weeks of the Doubleblind Treatment Phase for the EOD and daily
    rimegepant dosing regimens relative to P
    Evaluate the mean reduction from the Evaluate in the # of migraine dpm
    in the first 4weeks of the DBT Phase for the EOD and daily rimegepant
    dosing regimens relative to P
    Evaluate the mean # of acute migraine-specific medication dpm over the
    entire DBT for the EOD and daily rimegepant dosing regimens relative to
    P
    Evaluate the mean change from baseline in the Migraine-Specific
    Quality-of-Life Questionnaire restrictive role function domain score at
    W12
    Evaluate safety and tolerability of rimegepant
    Other objectives in the protocol
    Valutare la % di soggetti con riduzione >50% dal Fase di osservazione (OP) nei giorni di emicrania da moderata a grave per mese (dpm) su tutta la fase di trattamento in doppio cieco (DBT) per il EOD e regimi di dosaggio rimegepant giornalieri relativi al placebo (P)
    Valutare la riduzione media dal PO nel # di emicrania dpm nelle ultime 4 settimane della Fase di Trattamento Doubleblind per l'EOD e giornaliere rimegepant dosaggi relativi a P
    Valutare la riduzione media dal Valutare nel # di emicrania dpm nelle prime 4 settimane della fase DBT per l'EOD e rimegepant giornaliero regimi di dosaggio relativi a P
    Valutare la media # di acuta emicrania-farmaci specifici dpm sopra il DBT intero per i regimi di dosaggio EOD e rimegepant giornalieri relativi a P
    Valutare il cambiamento medio dalla linea di base nel Emicrania-Specifico
    Qualità della vita Questionario ruolo restrittivo punteggio dominio a W12
    Valutare la sicurezza e la tollerabilità di rimegepant
    Altri obiettivi del protocollo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Signed Written Informed Consent
    a)Written informed consent must be obtained from the subject in
    accordance with requirements of the study center's institutional review
    board (IRB) or ethics committee, prior to the initiation of any protocol
    required
    procedures.
    2.Target Population
    Subject has at least 1 year history of episodic migraine (with or without
    aura) consistent with a diagnosis according to the International
    Classification of Headache Disorders, 3rd Edition4, including the
    following:
    a)Age of onset of migraines prior to 50 years of age.
    b)Migraine attacks, on average, lasting 4 - 72 hours if untreated.
    c)Per subject report, 4-14 migraine attacks per month within the last 3
    months prior to the Screening Visit (month is defined as 4 weeks for the
    purpose of this protocol).
    d)4 or more migraine days during 28 days in the Observation Phase.
    e)Not more than 14 headache days during 28 days in the Observation
    Phase.
    f)Ability to distinguish migraine attacks from tension/cluster headaches.
    g)Subjects with contraindications for use of triptans may be included
    provided they meet all other study entry criteria.
    3.Age and Reproductive Status
    a)Male and female subjects = 18 years.
    b)Women of childbearing potential (WOCBP) and non-sterile men must
    be using two acceptable methods of contraception to avoid pregnancy
    throughout the study in such a manner that the risk of pregnancy is
    minimized. See Section 5.6 for the definition of WOCBP. Males with
    vasectomy are considered surgically sterile provided the procedure
    occurred greater than 6 months (24 weeks) prior to study participation.
    c)At the Baseline Visit, WOCBP must have a negative pregnancy test
    (minimum sensitivity 25 IU/L or equivalent units of HCG) before dosing
    with study drug.
    4.No clinically significant abnormality identified on the medical or
    laboratory evaluation. A subject with a clinical abnormality or laboratory
    parameters outside the reference range may be included only if the
    investigator considers the finding not clinically significant, that it will not
    introduce additional risk factors, nor interfere with the study procedures
    (not including exclusion criteria listed in Section 5.3 of the protocol).
    1.Consenso scritto informato firmato
    a) Il consenso scritto informato deve essere ottenuto dal soggetto in
    conformità ai requisiti della revisione istituzionale del centro studi
    consiglio (IRB) o comitato etico, prima dell'avvio di qualsiasi protocollo
    richiesto
    procedure.
    2.Popolazione bersaglio
    Il soggetto ha almeno 1 anno di storia di emicrania episodica (con o senza
    aura) coerente con una diagnosi secondo l'Internazionale
    Classificazione dei disordini di emicrania, terza Edition4, compreso il
    seguenti:
    a) Età di insorgenza delle emicranie prima dei 50 anni di età.
    b)Attacchi di emicrania, in media, della durata di 4 - 72 ore se non trattata.
    c)Per soggetto rapporto, 4-14 attacchi di emicrania al mese negli ultimi 3
    mesi prima della visita di screening (il mese è definito come 4 settimane
    finalità del presente protocollo).
    d)4 o più giorni di emicrania durante 28 giorni nella fase di osservazione.
    e)Non più di 14 giorni di mal di testa durante 28 giorni di osservazione
    Fase.
    f) Capacità di distinguere gli attacchi di emicrania da tensione/ cefalee a grappolo.
    g)I soggetti con controindicazioni per l'uso di triptani possono essere inclusi
    purché soddisfino tutti gli altri criteri di ammissione allo studio.
    3.Età e stato riproduttivo
    a)Soggetti maschi e femmine = 18 anni.
    b) Le donne con potenziale fertile (WOCBP) e gli uomini non sterili devono
    utilizzare due metodi contraccettivi accettabili per evitare la gravidanza
    durante tutto lo studio in modo tale che il rischio di gravidanza è
    minimizzato. Vedere Sezione 5.6 per la definizione di WOCBP. Maschi con
    vasectomia sono considerati chirurgicamente sterile a condizione che la procedura
    si è verificato più di 6 mesi (24 settimane) prima della partecipazione allo studio.
    c) Alla visita di riferimento, WOCBP deve avere un test di gravidanza negativo
    (sensibilità minima 25 UI/L o unità equivalenti di HCG) prima della somministrazione
    con droga di studio.
    4.Nessuna anomalia clinicamente significativa identificata sul medico o
    valutazione di laboratorio. Un soggetto con una anomalia clinica o di laboratorio
    parametri al di fuori della gamma di riferimento possono essere inclusi solo se il
    investigatore considera la scoperta non clinicamente significativo, che non sarà
    introdurre ulteriori fattori di rischio, né interferire con le procedure di studio
    (esclusi i criteri di esclusione elencati nella sezione 5.3 del protocollo).
    E.4Principal exclusion criteria
    1.Target Disease Exclusion
    a)Subject has a history of basilar migraine, hemiplegic migraine, retinal
    migraine or migraine accompanied by diplopia or decreased level of
    consciousness as defined by International Classification of Headache
    Disorders, 3rd Edition.
    b)Subjects with headaches occurring 15 or more days per month
    (migraine or non-migraine) in any of the 3 months prior to the Screening
    Visit.
    2.Medical History and Concurrent Diseases
    a)Subject history with current evidence of uncontrolled, unstable or
    recently diagnosed cardiovascular disease, such as ischemic heart
    disease, coronary artery vasospasm, and cerebral ischemia. Subjects
    with myocardial infarction, acute coronary syndrome, percutaneous
    coronary intervention, cardiac surgery, stroke or transient ischemic
    attack during the 6 months prior to the Screening Visit.
    b)Uncontrolled hypertension or uncontrolled diabetes. However,
    subjects can be included who have stable hypertension and/or diabetes
    for 3 months prior to the Screening Visit. Blood pressure greater than 150 mmHg systolic or 100 mmHg diastolic after 10 minutes of rest is
    exclusionary. This may be repeated once at screening once during visit
    to confirm reproducibility.
    c)Subjects with major depressive or any anxiety disorder which require
    more than 1 daily medication for each disorder or subjects with major
    depressive episode within last 12 months. Medications to treat major
    depressive disorder or an anxiety disorder must have been at a stable
    dose for at least 3 months prior to the Screening Visit.
    d)Active chronic pain syndromes
    e)Subjects with other pain syndromes (including trigeminal neuralgia),
    psychiatric conditions, dementia, or significant neurological disorders
    (other than migraine) that, in the Investigator's opinion, might interfere
    with study assessments of safety or efficacy.
    f)Diagnosis of active biliary disorder.
    g)Subject has a history of gastric, or small intestinal surgery, or has a
    disease or condition that causes malabsorption.
    h)Subject has a history or diagnosis of any active hepatic disorder.
    i)The subject has a history or current evidence of any unstable medical
    conditions that, in the investigator's opinion, would expose them to
    undue risk of a significant adverse event or interfere with assessments
    of safety or efficacy during the course of the study.
    j)History of, treatment for, or evidence of, alcohol or drug abuse within
    the past 12 months or subjects who have met DSM-V criteria10 for any
    significant substance use disorder within the past 12 months from the
    Screening Visit according to PI assessment.
    k)History of use of narcotics, such as opioids for =4 days per month
    during the 3 months prior to the Screening Visit.
    l)Subjects should be excluded if they have a positive drug screen for
    drugs of abuse that in the investigator's judgment is medically
    significant, in that it would impact the safety of the subject or the
    interpretation of the study results.
    m)Hematologic or solid malignancy diagnosis within 5 years prior to the
    Screening Visit. Subjects with a history of localized basal cell or
    squamous cell skin cancer are eligible for the study if they are cancer
    free
    prior to the Screening Visit in this study.
    n)Subject has current diagnosis of major depressive disorder requiring
    treatment with atypical antipsychotics, schizophrenia, bipolar disorder,
    or borderline personality disorder.
    o)Body mass index > 35.0 kg/m2.
    3.History of anaphylaxis to any substance or a clinically important
    reaction to any drug.
    4.Sex and Reproductive Status
    a)WOCBP who are unwilling or unable to use an acceptable
    contraceptive method or abstinence to avoid pregnancy for the entire
    study and for 60 days after the last dose of study drug.
    b)Women who are pregnant or breastfeeding.
    c)Women with a positive pregnancy test at screening or prior to study
    drug administration.
    5.ECG and Laboratory Test Findings
    a)Estimated glomerular filtration rate according to the re-expressed
    abbreviated Modification of Diet in Renal Disease Study equation = 30
    ml/min/1.73m2.
    b)Abnormal ECG that in the investigator's opinion makes the subject unsuitable for a clinical trial
    c)Total serum bilirubin > 1.5 x ULN.
    d)AST or ALT > 1.5 x ULN.
    e)Serum albumin < 2.8 g/dL.
    f)Neutrophil count = 1000/µL
    g)HbA1c > 7.5%
    6.Prohibited Medications
    a)Medication for migraine prophylaxis generally considered to have
    efficacy, regardless of indication, taken within 30 days prior the
    Screening Visit
    b)Analgesics taken = 15 days per month during the 3 months prior to
    the Screening Visit.
    c)Medication accepted for treatment of acute migraine for a non
    migraine
    indication taken = 15 days per month during the 3 months
    prior to the Screening Visit.
    d)Biologic migraine medication taken during the 6 months prior to the
    Screening Visit.
    e)Prohibited medication or device used during the Observation Phase
    For a complete exclusion criteria review please refer to the protocol.
    1.Esclusione della malattia bersaglio
    a)Il sogg ha una storia di emicrania basilare, emicrania emiplegica, retinale emicrania o emicrania accompagnata da diplopia o diminuzione del livello di coscienza come definito dalla ICHD, 3ed
    b) Soggetti con mal di testa che si verificano 15 o più giorni al mese nei 3 mesi precedenti lo screening.
    2.Storia medica e malattie concomitanti
    a)Storia del sogg con evidenza corrente di incontrollato, instabile o malattia cardiovas diagnosticata etc. Soggetti con infarto miocardico, sindrome coronarica acuta, percutanea
    intervento coronarico, chirurgia cardiaca, ictus o ischemico transitorio durante i 6 mesi precedenti la visita di screening.
    b)Ipertensione incontrollata o diabete incontrollato. Soggetti con ipertensione stabile e/o diabete
    per 3 mesi prima della visita di screening. La press arteriosa superiore a 150 mmHg sistolica o 100 mmHg diastolica dopo 10 minuti di riposo è
    esclusionario. Questo può essere ripetuto una volta allo screening durante la visita
    per confermare la riproducibilità.
    c)soggetti con depressivo maggiore o qualsiasi disturbo d'ansia che richiedono
    più di 1 farmaco al giorno per ogni disturbo o soggetti con maggiore
    episodio depressivo negli ultimi 12 mesi. Farmaci per il trattamento di maggiore
    disturbo depressivo o un disturbo d'ansia deve essere stato in una stalla
    per almeno 3 mesi prima della visita di screening.
    d)Sindromi dolorose croniche attive
    e)soggetti con altre sindromi dolorose (inclusa la nevralgia del trigemino),
    condizioni psichiatriche, demenza o disturbi neurologici significativi
    (oltre l'emicrania) che, secondo l'investigatore, potrebbe interferire
    con valutazioni di sicurezza o efficacia.
    f)Diagnosi di disturbo biliare attivo.
    g)Il soggetto ha una storia di chirurgia gastrica o intestinale, o ha un
    malattia o condizione che causa il malassorbimento.
    h)Il soggetto ha una storia o una diagnosi di qualsiasi disturbo epatico attivo.
    i)Il soggetto ha una storia o evidenza attuale di qualsiasi medico instabile
    condizioni che, secondo l'investigatore, li esporrebbe a
    rischio eccessivo di un evento avverso significativo o di interferire con le valutazioni
    sicurezza o efficacia durante lo studio.
    j)Precedenti, trattamenti o prove di abuso di alcol o di droga al l'interno del l'UE
    gli ultimi 12 mesi o soggetti che hanno soddisfatto i criteri DSM-V
    disturbo significativo uso di sostanze negli ultimi 12 mesi dalla
    Visita di screening secondo la valutazione PI.
    k)Storia dell'uso di stupefacenti, come gli oppioidi per =4 giorni al mese
    nei 3 mesi precedenti la visita di screening.
    l)I soggetti dovrebbero essere esclusi se hanno uno screening positivo per
    farmaci di abuso che a giudizio dell'investigatore è medico
    significativo, in quanto avrebbe un impatto sulla sicurezza del soggetto o il
    interpretazione dei risultati dello studio.
    m)Diagnosi di malignità ematologica o solida entro 5 anni prima della
    Visita di screening. Soggetti con una storia di cellule basali localizzate o
    cancro della pelle a cellule squamose sono ammissibili per lo studio se sono il cancro
    libero
    prima della visita di screening in questo studio.
    n) Il soggetto ha una diagnosi attuale di disturbo depressivo maggiore che richiede
    trattamento con antipsicotici atipici, schizofrenia, disturbo bipolare,
    o disturbo borderline di personalità.
    o)Indice di massa corporea > 35,0 kg/m2.
    3.Anafilassi di qualsiasi sostanza o un clinicamente importante
    reazione a qualsiasi farmaco.
    4.Sesso e stato riproduttivo
    a)WOCBP che sono disposti o incapaci di utilizzare un accettabile
    metodo contraccettivo o astinenza per evitare la gravidanza per l'intero
    studio e per 60 giorni dopo l'ultima dose di farmaco studio.
    b) Donne in gravidanza o in allattamento.
    c)Donne con un test di gravidanza positivo allo screening o prima dello studio
    somministrazione di farmaci.
    5.ECG e risultati delle prove di laboratorio
    a) Tasso di filtrazione glomerulare stimato in base alla ri-espressione
    Modifica abbreviata della dieta nell'equazione dello studio della malattia renale = 30
    ml/min/1.73m2.
    b) ECG anormale che, a parere del ricercatore, rende il soggetto inadatto a una sperimentazione clinica
    c)Bilirubina sierica totale > 1,5 x ULN.
    d)AST o ALT > 1,5 x ULN.
    e)Albumina sierica < 2,8 g/dl.
    f)Numero di neutrofili = 1000/µL
    g)HbA1c > 7,5%
    6.Farmaci proibiti
    a) Farmaci per la profilassi dell'emicrania generalmente considerati avere
    efficacia, indipendentemente dall'indicazione, presa entro 30 giorni prima del
    Visita di screening
    b)Analgesici assunti = 15 giorni al mese nei 3 mesi precedenti
    la visita di screening.
    c)Farmaco accettato per il trattamento di emicrania acuta per un non
    emicrania
    indicazione presa = 15 giorni al mese durante i 3 mesi
    prima della visita di screening.
    d)Farmaci biologici per l'emicrania assunti nei 6 mesi precedenti
    Screening Visita.
    e) Farmaci o dispositivi vietati durante la fase di osservazione
    Per una revisione completa dei criteri di esclusione fare riferimento al protocollo.
    E.5 End points
    E.5.1Primary end point(s)
    Mean change from the Observation Phase in the number of migraine days per month over the entire Double-blind Treatment Phase
    Variazione media rispetto alla Fase di osservazione nel numero di giorni di emicrania al mese nell’intera Fase di trattamento in doppio cieco
    E.5.1.1Timepoint(s) of evaluation of this end point
    Weeks 1 to 12
    Settimane da 1 a 12
    E.5.2Secondary end point(s)
    1. Proportion of subjects with = 50% reduction from the Observation Phase in the number of moderate to severe migraine days per month over the entire Double-blind Treatment Phase (Weeks 1 to 12).
    2. Mean change from the Observation Phase in the number of migraine days per month in the last 4 weeks (Weeks 9 to 12) of the Double-blind Treatment Phase.
    3. Mean change from the Observation Phase in the number of migraine days per month in the first 4 weeks (Weeks 1 to 4) of the Double-blind Treatment Phase.
    4. Mean number of acute migraine-specific medication days per month over the entire Double-blind Treatment Phase (Weeks 1 to 12). Acute migraine-specific medications are triptans and ergotamine.
    5. Mean change from baseline in the MSQ restrictive role function domain score at Week 12 of the Double-blind Treatment Phase.
    6. Number and percentage of subjects with AEs by intensity, serious adverse events (SAEs), AEs leading to study drug discontinuation, and grade 3 to 4 laboratory test abnormalities during the Double-blind Treatment and Open-label Extension Phases.
    7. Number and percentage of subjects treated with rimegepant with AST or ALT elevations > 3x ULN concurrent (i.e., on the same laboratory collection date) with total bilirubin > 2x ULN during the Double-blind Treatment and Open-label Extension Phases.
    8. Number and percentage of subjects treated with rimegepant with hepatic-related AEs by intensity, and hepatic-related AEs leading to study drug discontinuation during the Doubleblind Treatment and Open-label Extension Phases.
    1. Percentuale di soggetti con riduzione di = 50% della Fase di osservazione nel numero di giorni di emicrania da moderata a grave al mese nell’intera Fase di trattamento in doppio cieco (Settimane da 1 a 12).
    2. Variazione media rispetto alla Fase di osservazione nel numero di giorni di emicrania al mese nelle ultime 4 settimane (Settimane 9-12) della Fase di trattamento in doppio cieco.
    3. Variazione media dalla Fase di osservazione nel numero di giorni di emicrania al mese nelle prime 4 settimane (Settimane da 1 a 4) della Fase di trattamento in doppio cieco.
    4. Numero medio di giorni di farmaci sintomatici specifici per l’emicrania al mese nell’intera Fase di trattamento in doppio cieco (Settimane da 1 a 12). I farmaci sintomatici specifici per l’emicrania sono triptani ed ergotamina.
    5. Variazione media rispetto al basale nel punteggio del dominio della funzione di ruolo restrittivo dell’MSQ alla Settimana 12 della Fase di trattamento in doppio cieco.
    6. Numero e percentuale di soggetti con EA per intensità, eventi avversi seri (Serious Adverse Events, SAE), EA che portano all’interruzione del farmaco dello studio e anomalie negli esami di laboratorio di grado da 3 a 4 durante le Fasi di trattamento in doppio cieco e di estensione in aperto.
    7. Numero e percentuale di soggetti trattati con rimegepant con aumenti di AST o ALT > 3 volte l’ULN concomitanti (ovvero, alla stessa data di prelievo di laboratorio) con bilirubina totale > 2 volte l’ULN durante le Fasi di trattamento in doppio cieco e di estensione in aperto.
    8. Numero e percentuale di soggetti trattati con rimegepant con EA epatici per intensità ed EA epatici che portano all’interruzione del farmaco dello studio durante le fasi di trattamento in doppio cieco e di estensione in aperto.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the study
    Per tutta la durata dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    È prevista una fase opzionale di 12 settimane in aperto, dopo la fase di trattamento in doppio cieco
    There is an optional 12-week open-label phase, after the double-blind treatment phase
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Israel
    United Kingdom
    United States
    Austria
    France
    Germany
    Italy
    Poland
    Spain
    Sweden
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 624
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 36
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state78
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 330
    F.4.2.2In the whole clinical trial 660
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-09-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-07-26
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 20:59:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA